Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
Medicine (Baltimore)
; 97(27): e11331, 2018 Jul.
Article
en En
| MEDLINE
| ID: mdl-29979407
ABSTRACT
RATIONALE The JAK2 V617F mutation is frequently found in ET, while it is rare in de novo AML. ET has a low frequency of leukemic transformation. Both secondary AML (sAML) from ET and AML with JAK2 V617F mutation have poor prognoses. Because of the low incidence of JAK2 mutation in acute myeloid leukemia (AML), the clinical features of AML with JAK2 mutation are rarely reported so far, either transformed from essential thrombocythemia (ET) or de novo AML. PATIENT CONCERNS In this article, we present a pediatric AML patient with the JAK2 V617F mutation. DIAGNOSES A diagnosis of acute megakaryoblastic leukemia was made and sAML was ruled out. INTERVENTIONS:
The patient underwent chemotherapy.OUTCOMES:
In the first two complete remission periods, we found significantly increased numbers of platelets and bone marrow megakaryocytes, which are characteristic of ET. After the third chemotherapy phase, the disease relapsed; the platelet count was reduced and continued to decrease. When disease relapsed, her family abandoned treatment. LESSONS These observations of our case raise two possibilities either transient posttreatment thrombocythemia is a feature of AML with JAK2 V617F mutation, or this was a case of secondary AML. Additional information is required to reach better conclusions on the connection between AML and JAK2 mutations.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Leucemia Mieloide Aguda
/
Leucemia Megacarioblástica Aguda
/
Trombocitemia Esencial
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Female
/
Humans
/
Infant
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2018
Tipo del documento:
Article
País de afiliación:
China